The company's development strategy is to become the largest and most professional liposome preparation manufacturer in China, build a technical platform for targeted drug delivery systems (TDDS) such as liposomes, carry out the secondary development of drugs with market prospects, and gain market advantages of pharmaceutical products based on this core technology.
Daan Pharmaceutical Company has been put into production for three years, with standardized GMP management and perfect marketing network, and the sales of existing varieties have achieved rapid growth. The company has 1 179 commercial customers, including 94% at the provincial level, 52% at the prefecture level and 45% at the county level. Products have entered 4268 large and medium-sized hospitals in China, including 2 1% of tertiary hospitals, 25% of secondary hospitals, and 5% of primary hospitals and other hospitals. At present, it has participated in the bidding work in 29 provinces 158, with a total of 894 bids, with a participation rate of 100%. The winning bid rate is 68%, which is as high as 86% in the bidding areas of the whole province and municipalities directly under the Central Government.